

George Blanck

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7977592/george-blanck-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers

1,475
citations

16
h-index

35
g-index

98
ext. papers

1,694
ext. citations

5
avg, IF

4.65
L-index

#	Paper	IF	Citations
92	Specific TCR V-J gene segment recombinations leading to the identification pan-V-J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma.. <i>Leukemia and Lymphoma</i> , 2022 , 1-9	1.9	0
91	Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments.. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022 , 1-9	3.6	1
90	Immunogenomics Parameters for Patient Stratification in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022 , 1-11	4.3	1
89	Systemic Adaptive Immune Parameters Associated with Neuroblastoma Outcomes: the Significance of Gamma-Delta T Cells. <i>Journal of Molecular Neuroscience</i> , 2021 , 71, 2393-2404	3.3	2
88	Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates. <i>Translational Oncology</i> , 2021 , 14, 101069	4.9	4
87	A comparison of immune receptor recombination databases sourced from tumour exome or RNAseq files: Verifications of immunological distinctions between primary and metastatic melanoma. <i>International Journal of Immunogenetics</i> , 2021 , 48, 409-418	2.3	1
86	High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer. <i>Molecular Immunology</i> , 2021 , 135, 247-253	4.3	5
85	Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 591-600	4.4	3
84	Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas. <i>Pediatric Hematology and Oncology</i> , 2021 , 38, 251-264	1.7	5
83	Specific HLA alleles, paired with TCR V- and J-gene segment usage, link to distinct multiple myeloma survival rates. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1711-1720	1.9	2
82	Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis. <i>Viral Immunology</i> , 2020 , 33, 404-412	1.7	3
81	The ADC API: A Web API for the Programmatic Query of the AIRR Data Commons. <i>Frontiers in Big Data</i> , 2020 , 3, 22	2.8	12
80	Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. <i>Oncogene</i> , 2020 , 39, 1773-1783	9.2	9
79	Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates. <i>Cellular and Molecular Immunology</i> , 2020 , 17, 776-778	15.4	11
78	A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates. <i>Immunology</i> , 2020 , 159, 373-383	7.8	8
77	Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members. <i>Cancer Treatment and Research Communications</i> , 2020 , 24, 100196	2	1
76	TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates. <i>Human Immunology</i> , 2020 , 81, 692-696	2.3	1

75	B-cell Receptor Recombinations in Lung Adenocarcinoma Exome Files Correlate With a Higher Overall Survival Rate. <i>Anticancer Research</i> , 2020 , 40, 2043-2051	2.3	2
74	T-cell receptor V and J usage paired with specific HLA alleles associates with distinct cervical cancer survival rates. <i>Human Immunology</i> , 2019 , 80, 237-242	2.3	12
73	Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates. <i>Laboratory Investigation</i> , 2019 , 99, 1287-1295	5.9	5
72	An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia. <i>Cancer Cell International</i> , 2019 , 19, 73	6.4	3
71	Matrix-Metalloprotease Resistant Mucin-16 (MUC16) Peptide Mutants Represent a Worse Lung Adenocarcinoma Outcome. <i>Proteomics - Clinical Applications</i> , 2019 , 13, e1800155	3.1	4
70	TRAV gene segments further away from the TRAJ gene segment cluster appear more commonly in human tumor and blood samples. <i>Molecular Immunology</i> , 2019 , 116, 174-179	4.3	1
69	Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. <i>Breast Cancer Research and Treatment</i> , 2019 , 173, 167-177	4.4	11
68	MMP7 sensitivity of mutant ECM proteins: An indicator of melanoma survival rates and T-cell infiltration. <i>Clinical Biochemistry</i> , 2019 , 63, 85-91	3.5	3
67	T-cell receptor-CDR3 domain chemical features correlate with survival rates in bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 615-623	4.9	12
66	TRB-J1 usage, in combination with the HLA-A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates. <i>International Journal of Immunogenetics</i> , 2019 , 46, 31-37	2.3	7
65	MAPT (Tau) expression is a biomarker for an increased rate of survival for low-grade glioma. <i>Oncology Reports</i> , 2019 , 41, 1359-1366	3.5	14
64	T-cell receptor-IV and J usage, in combination with particular HLA class I and class II alleles, correlates with cancer survival patterns. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 885-892	7.4	16
63	Recovery of Immunoglobulin VJ Recombinations from Pancreatic Cancer Exome Files Strongly Correlates with Reduced Survival. <i>Cancer Microenvironment</i> , 2018 , 11, 51-59	6.1	13
62	T cell receptor-III usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates. <i>Immunologic Research</i> , 2018 , 66, 219-223	4.3	14
61	Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR-IV Recombinations. <i>Cancer Microenvironment</i> , 2018 , 11, 41-49	6.1	16
60	TcR-III recombinations in renal cell carcinoma exome files correlate with an intermediate level of T-cell exhaustion biomarkers. <i>International Immunology</i> , 2018 , 30, 35-40	4.9	13
59	Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir. <i>International Journal of Cancer</i> , 2018 , 142, 988-998	7.5	11
58	Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 459-468	4.9	5

57	Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome. <i>Oncology Letters</i> , 2018 , 16, 2757-2763	2.6	13
56	Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 503, 2218-2225	3.4	9
55	Germline cytoskeletal and extra-cellular matrix-related single nucleotide variations associated with distinct cancer survival rates. <i>Gene</i> , 2018 , 669, 91-98	3.8	1
54	High-level intrinsic disorder explains the universality of CLIP binding to diverse MHC class II variants. <i>Cellular and Molecular Immunology</i> , 2018 , 15, 76-78	15.4	1
53	MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma. <i>Cell Cycle</i> , 2018 , 17, 2474-2483	4.7	10
52	Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade. <i>Journal of Neuro-Oncology</i> , 2018 , 140, 697-704	4.8	19
51	Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2017 , 13, 501-506	4.4	22
50	Stratifying melanoma and breast cancer TCGA datasets on the basis of the CNV of transcription factor binding sites common to proliferation- and apoptosis-effector genes. <i>Gene</i> , 2017 , 614, 37-48	3.8	6
49	Assessing microenvironment immunogenicity using tumor specimen exomes: Co-detection of TcR-V(D)J recombinations correlates with PD-1 expression. <i>International Journal of Cancer</i> , 2017 , 140, 2568-2576	7.5	20
48	T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-V(D)J recombinations associates with a favorable oncologic outcome for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 403-410	7.4	18
47	The human, F-actin-based cytoskeleton as a mutagen sensor. <i>Cancer Cell International</i> , 2017 , 17, 121	6.4	5
46	, systemic, deleterious amino acid substitutions are common in large cytoskeleton-related protein coding regions. <i>Biomedical Reports</i> , 2017 , 6, 211-216	1.8	1
45	Protected cytoskeletal-related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer. <i>Biomedical Reports</i> , 2017 , 7, 163-168	1.8	4
44	Lung tumor exome files with T-cell receptor recombinations: a mouse model of T-cell infiltrates reflecting mutation burdens. <i>Laboratory Investigation</i> , 2017 , 97, 1516-1520	5.9	14
43	MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development. <i>Molecular and Clinical Oncology</i> , 2017 , 7, 1119-1121	1.6	6
42	Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome. <i>Current Genomics</i> , 2017 , 18, 287-297	2.6	3
41	HLA-DR peptide occupancy can be regulated with a wide variety of small molecules. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 593-8	4.4	0
40	Immunoscore by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA. <i>Cell and Tissue Research</i> , 2016 , 363, 491-6	4.2	10

39	Smoking correlates with increased cytoskeletal protein-related coding region mutations in the lung and head and neck datasets of the cancer genome atlas. <i>Physiological Reports</i> , 2016 , 4, e13045	2.6	9
38	TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma. <i>Cell Cycle</i> , 2016 , 15, 2157-2163 ⁶	4.7	6
37	Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens?. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 120-3	4.4	13
36	Detection of Productively Rearranged TcR- α -J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells. <i>Cancer Informatics</i> , 2016 , 15, 23-8	2.4	29
35	Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes: A multi-cancer approach. <i>Cell Cycle</i> , 2016 , 15, 1572-8	4.7	6
34	Overlap of the cancer genome atlas and the immune epitope database. <i>Oncology Letters</i> , 2016 , 12, 2982-2984		
33	Anticipating designer drug-resistant cancer cells. <i>Drug Discovery Today</i> , 2015 , 20, 790-3	8.8	8
32	Tumor suppressor genes are larger than apoptosis-effector genes and have more regions of active chromatin: Connection to a stochastic paradigm for sequential gene expression programs. <i>Cell Cycle</i> , 2015 , 14, 2494-500	4.7	7
31	Big genes are big mutagen targets: a connection to cancerous, spherical cells?. <i>Cancer Letters</i> , 2015 , 356, 479-82	9.9	19
30	Signal persistence and amplification in cancer development and possible, related opportunities for novel therapies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015 , 1855, 18-23	11.2	8
29	Copy number loss or silencing of apoptosis-effector genes in cancer. <i>Gene</i> , 2015 , 554, 50-7	3.8	12
28	Letter to the Editor: Giant proteins and cancer chemotherapy cardiotoxicity. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015 , 309, H718	5.2	1
27	Class II transactivator expression in melanoma cells facilitates T-cell engulfment. <i>Anticancer Research</i> , 2015 , 35, 25-9	2.3	3
26	A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates. <i>Cancer Genomics and Proteomics</i> , 2015 , 12, 283-90	3.3	9
25	Functionally distinct gene classes as bigger or smaller transcription factor traps: a possible stochastic component to sequential gene expression programs in cancer. <i>Gene</i> , 2014 , 536, 398-406	3.8	18
24	QUANTITATIVE MORPHOLOGICAL AND MOLECULAR PATHOLOGY OF THE HUMAN THYMUS CORRELATE WITH INFANT CAUSE OF DEATH. <i>Technology and Innovation</i> , 2014 , 16, 55-62	0.7	
23	The future of cancer research: prevention, screening, vaccines, and tumor-specific drug combos. <i>Human Vaccines and Immunotherapeutics</i> , 2014 , 10, 700-2	4.4	1
22	An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: towards a model of the cancer cell/B-cell microenvironment. <i>Experimental and Molecular Pathology</i> , 2014 , 97, 585-9	4.4	19

21	Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: cancer cell expression of HLA-DR. <i>Gene</i> , 2013 , 512, 403-7	3.8	4
20	Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2013 , 9, 784-9	4.4	13
19	Unifying the genomics-based classes of cancer fusion gene partners: large cancer fusion genes are evolutionarily conserved. <i>Cancer Genomics and Proteomics</i> , 2012 , 9, 389-95	3.3	3
18	Size matters: sequential mutations in tumorigenesis may reflect the stochastic effect of mutagen target sizes. <i>Genes and Cancer</i> , 2011 , 2, 927-31	2.9	15
17	Genes that contribute to cancer fusion genes are large and evolutionarily conserved. <i>Cancer Genetics and Cytogenetics</i> , 2009 , 191, 78-84		12
16	Substantially reduced expression of PIAS1 is associated with colon cancer development. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009 , 135, 1287-91	4.9	33
15	Combined IL-8 and TGF-beta blockade efficiently prevents neutrophil infiltrates into an A549-cell tumor. <i>Immunology Letters</i> , 2009 , 122, 26-9	4.1	7
14	Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit. <i>Molecular Immunology</i> , 2009 , 46, 569-75	4.3	5
13	A direct mechanistic link between growth control and a tumor cell immune function: increased interleukin-8 secretion accounts for elimination of Oct-1 antisense transformants from scid mice. <i>Anticancer Research</i> , 2006 , 26, 1733-8	2.3	2
12	CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells. <i>Anticancer Research</i> , 2005 , 25, 3889-92	2.3	7
11	Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. <i>Journal of Biological Chemistry</i> , 2004 , 279, 28911-9	5.4	21
10	Mutations and regulatory anomalies effecting tumor cell immune functions. <i>Cancer Immunology, Immunotherapy</i> , 2004 , 53, 1-16	7.4	9
9	Components of the IFN-gamma signaling pathway in tumorigenesis. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2002 , 50, 151-8	4	7
8	Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. <i>Oncogene</i> , 2001 , 20, 4219-27	9.2	19
7	High level class II trans-activator induction does not occur with transient activation of the IFN-gamma signaling pathway. <i>Journal of Immunology</i> , 2001 , 166, 1041-8	5.3	19
6	Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. <i>Molecular and Cellular Biology</i> , 2001 , 21, 6495-506	4.8	39
5	Interferon regulatory factor-2 point mutations in human pancreatic tumors. <i>International Journal of Cancer</i> , 2000 , 87, 803-808	7.5	15
4	Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. <i>Oncogene</i> , 1999 , 18, 5889-903	9.2	42

- | | | | |
|---|--|------|-----|
| 3 | IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. <i>Immunology and Cell Biology</i> , 1997 , 75, 325-32 | 5 | 21 |
| 2 | RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class II transactivator CIITA in class II non-inducible RB-defective tumor lines. <i>International Journal of Cancer</i> , 1995 , 62, 461-5 | 7.5 | 12 |
| 1 | A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. <i>Nature</i> , 1990 , 348, 744-7 | 50.4 | 609 |